Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation

Current Opinion in Cell Biology

Volumn 15, Issue 2, 2003, Pages 164-171

  Brooks, Christopher L ^a   Gu, Wei ^a,b  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ACETYLATION; APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL AGING; CELL GROWTH; GENOTOXICITY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; STRESS; TRANSCRIPTION INITIATION;

EID: 0037377060     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(03)00003-6     Document Type: Review

References (84)

1. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
2. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
3. Ryan K.M., Phillips A.C., Vousden K.H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13:2001;332-337.
4. Ashcroft M., Taya Y., Vousden K.H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell Biol. 20:2000;3224-3233.
5. Appella E., Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2001;2764-2772.
6. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14:2000;278-288.
7. Shieh S.Y., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14:2000;289-300.
8. Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:2000;1824-1827.
9. Buschmann T., Potapova O., Bar-Shira A., Ivanov V.N., Fuchs S.Y., Henderson S., Fried V.A., Minamoto T., Alarcon-Vargas D., Pincus M.R.et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell Biol. 21:2001;2743-2754.
10. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20:2001;1331-1340 This paper (together with [11]) shows that Mdm2 can inhibit CBP/p300-mediated acetylation of p53 both in vitro and in vivo. This inhibition is specific for p53 acetylation and occurs in response to a variety of stress-inducing agents.
11. Kobet E., Zeng X., Zhu Y., Keller D., Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA. 97:2000;12547-12552.
12. Rodriguez M.S., Desterro J.M., Lain S., Lane D.P., Hay R.T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell Biol. 20:2000;8458-8467.
13. Blattner C., Hay T., Meek D.W., Lane D.P. Hypophosphorylation of Mdm2 augments p53 stability. Mol. Cell Biol. 22:2002;6170-6182 The authors present strong evidence that Mdm2 is hypophosphorylated within the conserved region II in the central domain in response to ionizing radiation. Mutants of Mdm2 possessing alanine substitutions within this region were able to sufficiently ubiquitinate p53, but not degrade it. These results suggest an interesting model whereby phosphorylated Mdm2 recruits an unidentified factor required for p53 degradation but, upon DNA damage, dephosphorylation prevents this recruitment.
14. Kubbutat M.H., Ludwig R.L., Levine A.J., Vousden K.H. Analysis of the degradation function of Mdm2. Cell Growth Differ. 10:1999;87-92.
15. Argentini M., Barboule N., Wasylyk B. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene. 20:2001;1267-1275.
16. Zhu Q., Yao J., Wani G., Wani M.A., Wani A.A. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis. J. Biol. Chem. 276:2001;29695-29701.
17. Okamoto K., Li H., Jensen M.R., Zhang T., Taya Y., Thorgeirsson S.S., Prives C. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol. Cell. 9:2002;761-771 This paper identifies a role for cyclin G in recruiting phosphatase PP2A to dephosphorylate Mdm2 at Tyr216. They also show this specific dephosphorylation event enhances Mdm2 activity on p53.
18. Zhang Y., Xiong Y. Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ. 12:2001;175-186.
19. Pickart C.M. Ubiquitin in chains. Trends Biochem. Sci. 25:2000;544-548.
20. Gottifredi V., Prives C. Molecular biology. Getting p53 out of the nucleus. Science. 292:2001;1851-1852.
21. Michael D., Oren M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12:2002;53-59.
22. Vousden K.H., Woude G.F. The ins and outs of p53. Nat. Cell Biol. 2:2000;E178-E180.
23. Li L., Liao J., Ruland J., Mak T.W., Cohen S.N. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. USA. 98:2001;1619-1624.
24. Sionov R.V., Coen S., Goldberg Z., Berger M., Bercovich B., Ben-Neriah Y., Ciechanover A., Haupt Y. c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol. Cell Biol. 21:2001;5869-5878.
25. Li M., Chen D., Shiloh A., Luo J., Nikolaev A.Y., Qin J., Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 416:2002;648-653 Deubiquitination of p53 is shown to be an important antagonist of Mdm2-mediated degradation. HAUSP provides a novel pathway for p53 stabilization by directly blocking its ubiquitination, and this suggests a tumor suppressive role for HAUSP.
26. Seavey S.E., Holubar M., Saucedo L.J., Perry M.E. The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). J. Virol. 73:1999;7590-7598.
27. Tolbert D., Lu X., Yin C., Tantama M., Van Dyke T. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol. Cell. Biol. 22:2002;370-377.
28. Leung K.M., Po L.S., Tsang F.C., Siu W.Y., Lau A., Ho H.T., Poon R.Y. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res. 62:2002;4890-4893.
29. Hsieh J.K., Chan F.S., O'Connor D.J., Mittnacht S., Zhong S., Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell. 3:1999;181-193.
30. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA. 95:1998;8292-8297.
31. Sharp D.A., Kratowicz S.A., Sank M.J., George D.L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274:1999;38189-38196.
32. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
33. Lin A.W., Lowe S.W. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. USA. 98:2001;5025-5030.
34. •].
35. ARF can suppress Mdm2 activity without sequestering it in nucleoli.
36. Kubbutat M.H., Vousden K.H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell Biol. 17:1997;460-468.
37. Damalas A., Ben-Ze'ev A., Simcha I., Shtutman M., Leal J.F., Zhurinsky J., Geiger B., Oren M. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18:1999;3054-3063.
38. Fuchs S.Y., Adler V., Buschmann T., Yin Z., Wu X., Jones S.N., Ronai Z. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12:1998;2658-2663.
39. Zilfou J.T., Hoffman W.H., Sank M., George D.L., Murphy M. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol. Cell Biol. 21:2001;3974-3985.
40. Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. USA. 98:2001;1188-1193.
41. Asher G., Lotem J., Kama R., Sachs L., Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. USA. 99:2002;3099-3104.
42. Asher G., Lotem J., Sachs L., Kahana C., Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. USA. 99:2002;13125-13130.
43. •].
44. •].
45. •] use mouse models to show that MdmX functions as a negative regulator of p53 in vivo.
46. Ramos Y.F., Stad R., Attema J., Peltenburg L.T., van der Eb A.J., Jochemsen A.G. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res. 61:2001;1839-1842.
47. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., Campargue I., Naumovski L., Crook T., Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell. 8:2001;781-794 This paper identifies ASPP2, a member of the ASPP family of proteins, and shows that both ASPP1 and ASPP2 can enhance the transcriptional activation functions of p53. Additionally, these proteins augment p53 binding to the promoters of pro-apoptotic genes.
48. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y.et al. p53AIP1 a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:2000;849-862.
49. •].
50. •] show that homeodomain-interacting protein kinase-2 (HIPK2) is the kinase specifically responsible for phosphorylating Ser46 of p53 in response to UV irradiation. Furthermore, this phosphorylation event selectively promotes an apoptotic response.
51. Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., Lozano G., Zhao Y., Lu H. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell. 7:2001;283-292 This paper describes a protein complex that specifically phosphorylates Ser392 of p53 in response to UV irradiation.
52. Bulavin D.V., Saito S., Hollander M.C., Sakaguchi K., Anderson C.W., Appella E., Fornace A.J. Jr. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18:1999;6845-6854.
53. ••].
54. ••]) provide strong evidence for the phosphorylation-dependent role of Pin1 in bridging post-translational modifications and transcriptional activation of p53.
55. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19:2000;1176-1179.
56. Gu W., Shi X.L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature. 387:1997;819-823.
57. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature. 387:1997;823-827.
58. Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 89:1997;1175-1184.
59. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
60. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14:2000;1553-1577.
61. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64:2000;435-459.
62. Barlev N.A., Liu L., Chehab N.H., Mansfield K., Harris K.G., Halazonetis T.D., Berger S.L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell. 8:2001;1243-1254 The role of p53 acetylation in recruiting transcription factors and HATs to the p21 promoter in vivo is demonstrated here.
63. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
64. Jayaraman J., Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell. 81:1995;1021-1029.
65. Jayaraman L., Moorthy N.C., Murthy K.G., Manley J.L., Bustin M., Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 12:1998;462-472.
66. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:1998;2831-2841.
67. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell Biol. 19:1999;1202-1209.
68. Espinosa J.M., Emerson B.M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell. 8:2001;57-69 This paper suggests that the carboxyl terminus of p53 can act as a positive regulator in p53 transcriptional activation using an artificially reconstituted chromatin assay.
69. Crook T., Marston N.J., Sara E.A., Vousden K.H. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell. 79:1994;817-827.
70. Marston N.J., Crook T., Vousden K.H. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene. 9:1994;2707-2716.
71. McKinney K., Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell Biol. 22:2002;6797-6808.
72. Smith J. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 12:2002;404-406.
73. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 408:2000;377-381 This paper identifies the importance of deacetylase activity on p53. PID/MTA2 is shown to behave as a specific adaptor protein, linking HDAC1 activity with p53 deacetylation. The authors also show that this activity inhibits p53-mediated apoptosis and cell growth arrest.
74. Juan L.J., Shia W.J., Chen M.H., Yang W.M., Seto E., Lin Y.S., Wu C.W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275:2000;20436-20443.
75. ••].
76. ••].
77. ••] identify mammalian Sir2α as an NAD-dependent deacetylase that specifically deacetylates p53. Sir2α can also specifically repress a p53-dependent apoptotic response, underscoring its importance in p53 regulation.
78. Avalos J.L., Celic I., Muhammad S., Cosgrove M.S., Boeke J.D., Wolberger C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol. Cell. 10:2002;523-535.
79. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P.et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 406:2000;207-210.
80. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C.et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 415:2002;45-53.
81. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14:2000;1021-1026.
82. Katan-Khaykovich Y., Struhl K. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev. 16:2002;743-752.
83. Li M, Luo J, Brooks CL, Gu W: Acetylation of p53 inhibits its ubiquitination by Mdm2M. J Biol Chem 2002, in press.
84. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J. 21:2002;6236-6245.